Clinical Trials
23 trialsNCT04013685 2026-06-02
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
Phase 1 Active not recruiting
NCT07527221 2026-06-01
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
Eilean Therapeutics
Phase 1 Recruiting
NCT06092879 2026-05-29
ASSURE-3
Novartis
Active not recruiting
NCT05456191 2026-05-27
ASC4START
Novartis
Phase 3 Active not recruiting
NCT07354074 2026-05-26
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis
Phase 2 Recruiting
NCT05362773 2026-05-22
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
Phase 1 Recruiting
NCT07454850 2026-05-18
A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait
Novartis
Not yet recruiting
NCT07549516 2026-05-15
ASC2ADHERE
Novartis
Recruiting
NCT02629692 2026-05-13
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Sun Pharma Advanced Research Company Limited
Phase 1/2 Terminated
NCT04877522 2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting
NCT04925479 2026-04-30
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Novartis
Phase 1/2 Recruiting
NCT03578367 2026-04-21
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Phase 2 Completed
NCT06514534 2026-04-21
ASC4TARGET
Novartis
Phase 2 Recruiting
NCT05943522 2026-04-20
Asciminib RMP Study
Novartis
Recruiting
NCT06427811 2026-04-17
ASC4INDIA
Novartis
Phase 4 Completed
NCT06297161 2026-04-14
A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).
Pfizer
Recruiting
NCT04971226 2026-04-06
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
NCT03874858 2026-04-02
DANTE
Novartis
Phase 2 Completed
NCT05304377 2026-04-01
CML
Enliven Therapeutics
Phase 1 Recruiting
NCT07489755 2026-03-24
TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients
Shenzhen TargetRx Co., Ltd.
Phase 3 Not yet recruiting
NCT04948333 2026-03-18
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Phase 3 Completed
NCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT06994676 2026-03-16
CROSSCHECK-001
Crossbow Therapeutics, Inc.
Phase 1 Recruiting